CD86 and colorectal cancer: Multiplex immunofluorescence (mIF) quantification revealed significantly increased densities of both CD68+CD86+ and CD68+CD163+ TAMs, and a higher CD68+CD163+/CD68+CD86+ ratio in colorectal cancer (CRC) (all P < 0.001).